BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Sala M, Bruix J. Nonsurgical treatment of hepatocellular carcinoma. Liver Transpl 2000;6:s11-5. [DOI: 10.1053/jlts.2000.18684] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R, Wust P, Lopez-hänninen E, Gademann G, Peters N, Berg T, Malfertheiner P, Ricke J. Computed Tomography–Guided High-Dose-Rate Brachytherapy in Hepatocellular Carcinoma: Safety, Efficacy, and Effect on Survival. International Journal of Radiation Oncology*Biology*Physics 2010;78:172-9. [DOI: 10.1016/j.ijrobp.2009.07.1700] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
2 Yu HC, Moon JI, Jin ZW, Lee DY, Kim CY, Song CH, Cho BH. Effect of radiofrequency ablation of the liver on cell-mediated immunity in rats. World J Surg. 2005;29:739-743. [PMID: 15880280 DOI: 10.1007/s00268-005-7728-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
3 Kuntz E, Kuntz H. Malignant liver tumours. Hepatology. Berlin: Springer Berlin Heidelberg; 2002. pp. 699-730. [DOI: 10.1007/978-3-662-04680-7_37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Donckier V, Van Laethem JL, Van Gansbeke D, Ickx B, Lingier P, Closset J, El Nakadi I, Feron P, Boon N, Bourgeois N, Adler M, Gelin M. New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients. J Surg Oncol 2003;84:36-44. [DOI: 10.1002/jso.10281] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
5 Poon RT, Fan ST, Ng IO, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg. 2003;237:376-383. [PMID: 12616122 DOI: 10.1097/01.sla.0000055224.68432.80] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
6 Shi H, Lambert JM, Hautefeuille A, Bykov VJ, Wiman KG, Hainaut P, de Fromentel CC. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis 2008;29:1428-34. [DOI: 10.1093/carcin/bgm266] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
7 J. Cheng S, Pratt DS, Freeman RB, Kaplan MM, Wong JB. LIVING-DONOR VERSUS CADAVERIC LIVER TRANSPLANTATION FOR NON-RESECTABLE SMALL HEPATOCELLULAR CARCINOMA AND COMPENSATED CIRRHOSIS: A DECISION ANALYSIS1: . Transplantation 2001;72:861-8. [DOI: 10.1097/00007890-200109150-00021] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 4.0] [Reference Citation Analysis]
8 Wong LL. Current status of liver transplantation for hepatocellular cancer. Am J Surg. 2002;183:309-316. [PMID: 11943133 DOI: 10.1016/s0002-9610(02)00785-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
9 Cheung TT, Ng KK, Chok KS, Chan SC, Poon RT, Lo CM, Fan ST. Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: Prognosis and outcomes. World J Gastroenterol 2010; 16(24): 3056-3062 [PMID: 20572310 DOI: 10.3748/wjg.v16.i24.3056] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
10 Romanque P, Piguet AC, Dufour JF. Targeting vessels to treat hepatocellular carcinoma. Clin Sci (Lond). 2008;114:467-477. [PMID: 18302534 DOI: 10.1042/CS20070310] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Ye Z, Wang X, Hao S, Zhong J, Xiang J, Yang J. Oncolytic adenovirus-mediated E1A gene therapy induces tumor-cell apoptosis and reduces tumor angiogenesis leading to inhibition of hepatocellular carcinoma growth in animal model. Cancer Biother Radiopharm. 2006;21:225-234. [PMID: 16918299 DOI: 10.1089/cbr.2006.21.225] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kim J, Lee B, Kim JS, Yun CO, Kim JH, Lee YJ, Joo CH, Lee H. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett. 2002;180:23-32. [PMID: 11911966 DOI: 10.1016/s0304-3835(02)00017-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
13 Cheng H, Liu YF, Zhang HZ, Shen WA, Zhang J, Zhang J. In vivo antitumour activity of PBMCs via genetic modification of single-chain immunotoxin. Shijie Huaren Xiaohua Zazhi 2003; 11(6): 708-711 [DOI: 10.11569/wcjd.v11.i6.708] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Bahl A, Kapoor R, Singh PK, Bhattacharya T, Arun OS, Parsee T, Sharma SC. Locally ablative non-surgical management of colo-rectal liver metastasis. J Gastrointest Cancer 2013;44:108-10. [PMID: 22864942 DOI: 10.1007/s12029-012-9427-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Cheng H, Liu YF, Zhang HZ, Shen WA, Zhang J, Zhang J. In vitro cytotoxicity of PBMCs via genetic modification of single-chain immunotoxin. Shijie Huaren Xiaohua Zazhi 2003; 11(3): 281-284 [DOI: 10.11569/wcjd.v11.i3.281] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Gaitantzi H, Meyer C, Rakoczy P, Thomas M, Wahl K, Wandrer F, Bantel H, Alborzinia H, Wölfl S, Ehnert S, Nüssler A, Bergheim I, Ciuclan L, Ebert M, Breitkopf-Heinlein K, Dooley S. Ethanol sensitizes hepatocytes for TGF-β-triggered apoptosis. Cell Death Dis 2018;9:51. [PMID: 29352207 DOI: 10.1038/s41419-017-0071-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
17 Jansen PL. Liver disease in the elderly. Best Pract Res Clin Gastroenterol. 2002;16:149-158. [PMID: 11977934 DOI: 10.1053/bega.2002.0271] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
18 Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:55-63. [PMID: 23182627 DOI: 10.1016/s1470-2045(12)70490-4] [Cited by in Crossref: 397] [Cited by in F6Publishing: 218] [Article Influence: 39.7] [Reference Citation Analysis]
19 Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8:1165-1174. [PMID: 12474157 DOI: 10.1053/jlts.2002.36394] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 6.2] [Reference Citation Analysis]